ID   ABCG2_HUMAN             Reviewed;         655 AA.
AC   Q9UNQ0; A0A1W3; A8K1T5; O95374; Q4W5I3; Q53ZQ1; Q569L4; Q5YLG4;
AC   Q86V64; Q8IX16; Q96LD6; Q96TA8; Q9BY73; Q9NUS0;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 3.
DT   10-MAY-2017, entry version 174.
DE   RecName: Full=ATP-binding cassette sub-family G member 2;
DE   AltName: Full=Breast cancer resistance protein;
DE   AltName: Full=CDw338;
DE   AltName: Full=Mitoxantrone resistance-associated protein;
DE   AltName: Full=Placenta-specific ATP-binding cassette transporter;
DE   AltName: Full=Urate exporter;
DE   AltName: CD_antigen=CD338;
GN   Name=ABCG2; Synonyms=ABCP, BCRP, BCRP1, MXR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS GLU-166 AND SER-208,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=9850061;
RA   Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M.;
RT   "A human placenta-specific ATP-binding cassette gene (ABCP) on
RT   chromosome 4q22 that is involved in multidrug resistance.";
RL   Cancer Res. 58:5337-5339(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary cancer;
RX   PubMed=9861027; DOI=10.1073/pnas.95.26.15665;
RA   Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K.,
RA   Ross D.D.;
RT   "A multidrug resistance transporter from human MCF-7 breast cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:15665-15670(1998).
RN   [3]
RP   ERRATUM.
RA   Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K.,
RA   Ross D.D.;
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2569-2569(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T.,
RA   Sugimoto Y.;
RT   "Breast cancer resistance protein constitutes a 140-kDa complex as a
RT   homodimer.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11306452;
RA   Komatani H., Kotani H., Hara Y., Nakagawa R., Matsumoto M.,
RA   Arakawa H., Nishimura S.;
RT   "Identification of breast cancer resistant protein/mitoxantrone
RT   resistance/placenta-specific, ATP-binding cassette transporter as a
RT   transporter of NB-506 and J-107088, topoisomerase I inhibitors with an
RT   indolocarbazole structure.";
RL   Cancer Res. 61:2827-2832(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11533706; DOI=10.1038/nm0901-1028;
RA   Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J.,
RA   Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H.,
RA   Sorrentino B.P.;
RT   "The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of
RT   stem cells and is a molecular determinant of the side-population
RT   phenotype.";
RL   Nat. Med. 7:1028-1034(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND VARIANTS GLU-166
RP   AND SER-208.
RC   TISSUE=Brain endothelium;
RX   PubMed=12958161; DOI=10.1096/fj.02-1131fje;
RA   Zhang W., Mojsilovic-Petrovic J., Andrade M.F., Zhang H., Ball M.,
RA   Stanimirovic D.B.;
RT   "The expression and functional characterization of ABCG2 in brain
RT   endothelial cells and vessels.";
RL   FASEB J. 17:2085-2087(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LYS-141.
RA   Yoshikawa M., Yabuuchi H., Ikegami Y., Ishikawa T.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PRO-316.
RA   Sudarikov A., Makarik T., Andreeff M.;
RT   "Cell line K562 resistant to Hoechst 33342.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-12; LYS-141;
RP   HIS-296 AND THR-528.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   LYS-141.
RC   TISSUE=Pancreas, and PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 294-655 (ISOFORM 1).
RX   PubMed=9892175;
RA   Miyake K., Mickley L., Litman T., Zhan Z., Robey R.W., Cristensen B.,
RA   Brangi M., Greenberger L., Dean M., Fojo T., Bates S.E.;
RT   "Molecular cloning of cDNAs which are highly overexpressed in
RT   mitoxantrone-resistant cells: demonstration of homology to ABC
RT   transport genes.";
RL   Cancer Res. 59:8-13(1999).
RN   [15]
RP   REVIEW.
RX   PubMed=11590207;
RA   Schmitz G., Langmann T., Heimerl S.;
RT   "Role of ABCG1 and other ABCG family members in lipid metabolism.";
RL   J. Lipid Res. 42:1513-1520(2001).
RN   [16]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15001581; DOI=10.1074/jbc.M310785200;
RA   Xu J., Liu Y., Yang Y., Bates S., Zhang J.T.;
RT   "Characterization of oligomeric human half-ABC transporter ATP-binding
RT   cassette G2.";
RL   J. Biol. Chem. 279:19781-19789(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-596, LACK OF GLYCOSYLATION
RP   AT ASN-418 AND ASN-557, AND MUTAGENESIS OF ASN-418; ASN-557 AND
RP   ASN-596.
RX   PubMed=15807535; DOI=10.1021/bi0479858;
RA   Diop N.K., Hrycyna C.A.;
RT   "N-linked glycosylation of the human ABC transporter ABCG2 on
RT   asparagine 596 is not essential for expression, transport activity, or
RT   trafficking to the plasma membrane.";
RL   Biochemistry 44:5420-5429(2005).
RN   [18]
RP   MUTAGENESIS OF ARG-482.
RX   PubMed=15670731; DOI=10.1016/j.bbamem.2004.11.005;
RA   Oezvegy-Laczka C., Koebloes G., Sarkadi B., Varadi A.;
RT   "Single amino acid (482) variants of the ABCG2 multidrug transporter:
RT   major differences in transport capacity and substrate recognition.";
RL   Biochim. Biophys. Acta 1668:53-63(2005).
RN   [19]
RP   MUTAGENESIS OF LYS-86, SUBCELLULAR LOCATION, AND HOMODIMERIZATION.
RX   PubMed=15769853; DOI=10.1242/jcs.01729;
RA   Henriksen U., Gether U., Litman T.;
RT   "Effect of Walker A mutation (K86M) on oligomerization and surface
RT   targeting of the multidrug resistance transporter ABCG2.";
RL   J. Cell Sci. 118:1417-1426(2005).
RN   [20]
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=17686774; DOI=10.1074/jbc.C700133200;
RA   Wakabayashi K., Nakagawa H., Tamura A., Koshiba S., Hoshijima K.,
RA   Komada M., Ishikawa T.;
RT   "Intramolecular disulfide bond is a critical check point determining
RT   degradative fates of ATP-binding cassette (ABC) transporter ABCG2
RT   protein.";
RL   J. Biol. Chem. 282:27841-27846(2007).
RN   [21]
RP   POLYMORPHISM, AND INVOLVEMENT IN UAQTL1 AND GOUT.
RX   PubMed=18834626; DOI=10.1016/S0140-6736(08)61343-4;
RA   Dehghan A., Kottgen A., Yang Q., Hwang S.J., Kao W.L., Rivadeneira F.,
RA   Boerwinkle E., Levy D., Hofman A., Astor B.C., Benjamin E.J.,
RA   van Duijn C.M., Witteman J.C., Coresh J., Fox C.S.;
RT   "Association of three genetic loci with uric acid concentration and
RT   risk of gout: a genome-wide association study.";
RL   Lancet 372:1953-1961(2008).
RN   [22]
RP   POLYMORPHISM, INVOLVEMENT IN UAQTL1, ASSOCIATION OF VARIANT LYS-141
RP   WITH GOUT, AND CHARACTERIZATION OF VARIANT LYS-141.
RX   PubMed=19506252; DOI=10.1073/pnas.0901249106;
RA   Woodward O.M., Kottgen A., Coresh J., Boerwinkle E., Guggino W.B.,
RA   Kottgen M.;
RT   "Identification of a urate transporter, ABCG2, with a common
RT   functional polymorphism causing gout.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10338-10342(2009).
RN   [23]
RP   POLYMORPHISM, INVOLVEMENT IN UAQTL1, AND ASSOCIATION OF VARIANT
RP   LYS-141 WITH GOUT.
RX   PubMed=20368174; DOI=10.1126/scitranslmed.3000237;
RA   Matsuo H., Takada T., Ichida K., Nakamura T., Nakayama A.,
RA   Ikebuchi Y., Ito K., Kusanagi Y., Chiba T., Tadokoro S., Takada Y.,
RA   Oikawa Y., Inoue H., Suzuki K., Okada R., Nishiyama J., Domoto H.,
RA   Watanabe S., Fujita M., Morimoto Y., Naito M., Nishio K., Hishida A.,
RA   Wakai K., Asai Y., Niwa K., Kamakura K., Nonoyama S., Sakurai Y.,
RA   Hosoya T., Kanai Y., Suzuki H., Hamajima N., Shinomiya N.;
RT   "Common defects of ABCG2, a high-capacity urate exporter, cause gout:
RT   a function-based genetic analysis in a Japanese population.";
RL   Sci. Transl. Med. 1:5ra11-5ra11(2009).
RN   [24]
RP   FUNCTION, DOMAIN, AND MUTAGENESIS OF HIS-583; CYS-603 AND TYR-605.
RX   PubMed=20705604; DOI=10.1074/jbc.M110.139170;
RA   Desuzinges-Mandon E., Arnaud O., Martinez L., Huche F., Di Pietro A.,
RA   Falson P.;
RT   "ABCG2 transports and transfers heme to albumin through its large
RT   extracellular loop.";
RL   J. Biol. Chem. 285:33123-33133(2010).
RN   [25]
RP   FUNCTION.
RX   PubMed=22132962; DOI=10.1080/15257770.2011.633953;
RA   Nakayama A., Matsuo H., Takada T., Ichida K., Nakamura T.,
RA   Ikebuchi Y., Ito K., Hosoya T., Kanai Y., Suzuki H., Shinomiya N.;
RT   "ABCG2 is a high-capacity urate transporter and its genetic impairment
RT   increases serum uric acid levels in humans.";
RL   Nucleosides Nucleotides Nucleic Acids 30:1091-1097(2011).
RN   [26]
RP   REVIEW.
RX   PubMed=22509477;
RA   Mo W., Zhang J.T.;
RT   "Human ABCG2: structure, function, and its role in multidrug
RT   resistance.";
RL   Int. J. Biochem. Mol. Biol. 3:1-27(2012).
RN   [27]
RP   POLYMORPHISM, INVOLVEMENT IN JR, AND VARIANT MET-12.
RX   PubMed=22246507; DOI=10.1038/ng.1075;
RA   Zelinski T., Coghlan G., Liu X.Q., Reid M.E.;
RT   "ABCG2 null alleles define the Jr(a-) blood group phenotype.";
RL   Nat. Genet. 44:131-132(2012).
RN   [28]
RP   POLYMORPHISM, AND INVOLVEMENT IN JR.
RX   PubMed=22246505; DOI=10.1038/ng.1070;
RA   Saison C., Helias V., Ballif B.A., Peyrard T., Puy H., Miyazaki T.,
RA   Perrot S., Vayssier-Taussat M., Waldner M., Le Pennec P.Y.,
RA   Cartron J.P., Arnaud L.;
RT   "Null alleles of ABCG2 encoding the breast cancer resistance protein
RT   define the new blood group system Junior.";
RL   Nat. Genet. 44:174-177(2012).
RN   [29]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23189181; DOI=10.1371/journal.pone.0050082;
RA   Kobuchi H., Moriya K., Ogino T., Fujita H., Inoue K., Shuin T.,
RA   Yasuda T., Utsumi K., Utsumi T.;
RT   "Mitochondrial localization of ABC transporter ABCG2 and its function
RT   in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation.";
RL   PLoS ONE 7:E50082-E50082(2012).
RN   [30]
RP   VARIANTS MET-12 AND LYS-141.
RX   PubMed=12111378; DOI=10.1007/s100380200041;
RA   Iida A., Saito S., Sekine A., Mishima C., Kitamura Y., Kondo K.,
RA   Harigae S., Osawa S., Nakamura Y.;
RT   "Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes
RT   encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8,
RT   ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and
RT   ABCG8.";
RL   J. Hum. Genet. 47:285-310(2002).
RN   [31]
RP   VARIANTS LEU-431 AND LEU-489.
RX   PubMed=15618737; DOI=10.2133/dmpk.18.212;
RA   Itoda M., Saito Y., Shirao K., Minami H., Ohtsu A., Yoshida T.,
RA   Saijo N., Suzuki H., Sugiyama Y., Ozawa S., Sawada J.;
RT   "Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese
RT   cancer patients administered irinotacan.";
RL   Drug Metab. Pharmacokinet. 18:212-217(2003).
RN   [32]
RP   VARIANTS MET-12; LYS-141; LEU-206 AND TYR-590.
RX   PubMed=12544509; DOI=10.1097/00008571-200301000-00004;
RA   Zamber C.P., Lamba J.K., Yasuda K., Farnum J., Thummel K.,
RA   Schuetz J.D., Schuetz E.G.;
RT   "Natural allelic variants of breast cancer resistance protein (BCRP)
RT   and their relationship to BCRP expression in human intestine.";
RL   Pharmacogenetics 13:19-28(2003).
RN   [33]
RP   CHARACTERIZATION OF VARIANTS MET-12; LYS-141 AND ASN-620.
RX   PubMed=15838659; DOI=10.1007/s00280-004-0931-x;
RA   Morisaki K., Robey R.W., Oezvegy-Laczka C., Honjo Y., Polgar O.,
RA   Steadman K., Sarkadi B., Bates S.E.;
RT   "Single nucleotide polymorphisms modify the transporter activity of
RT   ABCG2.";
RL   Cancer Chemother. Pharmacol. 56:161-172(2005).
RN   [34]
RP   VARIANTS MET-12; LEU-13; LYS-141; GLN-160; ARG-354; LEU-431; ASN-441
RP   AND LEU-489.
RX   PubMed=16702730; DOI=10.2133/dmpk.21.109;
RA   Maekawa K., Itoda M., Sai K., Saito Y., Kaniwa N., Shirao K.,
RA   Hamaguchi T., Kunitoh H., Yamamoto N., Tamura T., Minami H.,
RA   Kubota K., Ohtsu A., Yoshida T., Saijo N., Kamatani N., Ozawa S.,
RA   Sawada J.;
RT   "Genetic variation and haplotype structure of the ABC transporter gene
RT   ABCG2 in a Japanese population.";
RL   Drug Metab. Pharmacokinet. 21:109-121(2006).
CC   -!- FUNCTION: High-capacity urate exporter functioning in both renal
CC       and extrarenal urate excretion. Plays a role in porphyrin
CC       homeostasis as it is able to mediates the export of protoporhyrin
CC       IX (PPIX) both from mitochondria to cytosol and from cytosol to
CC       extracellular space, and cellular export of hemin, and heme.
CC       Xenobiotic transporter that may play an important role in the
CC       exclusion of xenobiotics from the brain. Appears to play a major
CC       role in the multidrug resistance phenotype of several cancer cell
CC       lines. Implicated in the efflux of numerous drugs and xenobiotics:
CC       mitoxantrone, the photosensitizer pheophorbide, camptothecin,
CC       methotrexate, azidothymidine (AZT), and the anthracyclines
CC       daunorubicin and doxorubicin. {ECO:0000269|PubMed:12958161,
CC       ECO:0000269|PubMed:20705604, ECO:0000269|PubMed:22132962,
CC       ECO:0000269|PubMed:23189181}.
CC   -!- SUBUNIT: Monomer under reducing conditions, the minimal functional
CC       units is a homodimer; disulfide-linked, but the major oligomeric
CC       form in plasma membranes is a homotetramer with possibility of
CC       higher order oligomerization up to homododecamers.
CC       {ECO:0000269|PubMed:15001581, ECO:0000269|PubMed:17686774}.
CC   -!- INTERACTION:
CC       P11309-1:PIM1; NbExp=9; IntAct=EBI-1569435, EBI-1018629;
CC       P0CG48:UBC; NbExp=2; IntAct=EBI-1569435, EBI-3390054;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15001581,
CC       ECO:0000269|PubMed:15769853, ECO:0000269|PubMed:15807535}; Multi-
CC       pass membrane protein {ECO:0000255}. Mitochondrion membrane
CC       {ECO:0000269|PubMed:23189181}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UNQ0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UNQ0-2; Sequence=VSP_014232, VSP_014233;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta. Low expression
CC       in small intestine, liver and colon. {ECO:0000269|PubMed:9850061,
CC       ECO:0000269|PubMed:9861027}.
CC   -!- INDUCTION: Up-regulated in brain tumors.
CC   -!- DOMAIN: The extracellular loop 3 (ECL3) is involved in binding
CC       porphyrins and transfer them to other carriers, probably albumin.
CC       {ECO:0000269|PubMed:20705604}.
CC   -!- PTM: Glycosylation-deficient ABCG2 is normally expressed and
CC       functional. {ECO:0000269|PubMed:15807535}.
CC   -!- POLYMORPHISM: Genetic variations in ABCG2 define the blood group
CC       Junior system (JR) [MIM:614490]. Individuals with Jr(a-) blood
CC       group lack the Jr(a) antigen on their red blood cells. These
CC       individuals may have anti-Jr(a) antibodies in their serum, which
CC       can cause transfusion reactions or hemolytic disease of the fetus
CC       or newborn. Although the clinical significance of the Jr(a-) blood
CC       group has been controversial, severe fatal hemolytic disease of
CC       the newborn has been reported. The Jr(a-) phenotype has a higher
CC       frequency in individuals of Asian descent, compared to those of
CC       European descent. The Jr(a-) phenotype is inherited as an
CC       autosomal recessive trait. {ECO:0000269|PubMed:22246505,
CC       ECO:0000269|PubMed:22246507}.
CC   -!- POLYMORPHISM: Genetic variations in ABCG2 influence the variance
CC       in serum uric acid concentrations and define the serum uric acid
CC       concentration quantitative trait locus 1 (UAQTL1) [MIM:138900].
CC       Excess serum accumulation of uric acid can lead to the development
CC       of gout, a common disorder characterized by tissue deposition of
CC       monosodium urate crystals as a consequence of hyperuricemia
CC       (PubMed:18834626, PubMed:19506252, PubMed:20368174).
CC       {ECO:0000269|PubMed:18834626, ECO:0000269|PubMed:19506252,
CC       ECO:0000269|PubMed:20368174}.
CC   -!- MISCELLANEOUS: When overexpressed, the transfected cells become
CC       resistant to mitoxantrone, daunorubicin and doxorubicin.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCG
CC       family. Eye pigment precursor importer (TC 3.A.1.204) subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AF093771; Type=Frameshift; Positions=486, 586; Evidence={ECO:0000305};
CC       Sequence=AF093772; Type=Frameshift; Positions=386, 502, 586; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/abcg2/";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q9UNQ0";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF103796; AAD09188.1; -; mRNA.
DR   EMBL; AF098951; AAC97367.1; -; mRNA.
DR   EMBL; AB056867; BAB39212.1; -; mRNA.
DR   EMBL; AB051855; BAB46933.1; -; mRNA.
DR   EMBL; AY017168; AAG52982.1; -; mRNA.
DR   EMBL; AY289766; AAP44087.1; -; mRNA.
DR   EMBL; AY288307; AAP31310.1; -; mRNA.
DR   EMBL; AF463519; AAO14617.1; -; mRNA.
DR   EMBL; AY333755; AAQ92941.1; -; mRNA.
DR   EMBL; AY333756; AAQ92942.1; -; mRNA.
DR   EMBL; AK002040; BAA92050.1; -; mRNA.
DR   EMBL; AK290000; BAF82689.1; -; mRNA.
DR   EMBL; DQ996467; ABI97388.1; -; Genomic_DNA.
DR   EMBL; AC084732; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC097484; AAY40902.1; -; Genomic_DNA.
DR   EMBL; BC021281; AAH21281.1; -; mRNA.
DR   EMBL; BC092408; AAH92408.1; -; mRNA.
DR   EMBL; AF093771; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AF093772; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS3628.1; -. [Q9UNQ0-1]
DR   CCDS; CCDS58910.1; -. [Q9UNQ0-2]
DR   RefSeq; NP_001244315.1; NM_001257386.1. [Q9UNQ0-2]
DR   RefSeq; NP_004818.2; NM_004827.2. [Q9UNQ0-1]
DR   RefSeq; XP_005263412.1; XM_005263355.3. [Q9UNQ0-1]
DR   RefSeq; XP_011530722.1; XM_011532420.2. [Q9UNQ0-1]
DR   UniGene; Hs.480218; -.
DR   ProteinModelPortal; Q9UNQ0; -.
DR   BioGrid; 114821; 17.
DR   DIP; DIP-29162N; -.
DR   IntAct; Q9UNQ0; 19.
DR   MINT; MINT-2840423; -.
DR   STRING; 9606.ENSP00000237612; -.
DR   BindingDB; Q9UNQ0; -.
DR   ChEMBL; CHEMBL5393; -.
DR   DrugBank; DB08916; Afatinib.
DR   DrugBank; DB11363; Alectinib.
DR   DrugBank; DB06605; Apixaban.
DR   DrugBank; DB04851; Biricodar dicitrate.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB06772; Cabazitaxel.
DR   DrugBank; DB04690; Camptothecin.
DR   DrugBank; DB00958; Carboplatin.
DR   DrugBank; DB00439; Cerivastatin.
DR   DrugBank; DB04540; Cholesterol.
DR   DrugBank; DB00515; Cisplatin.
DR   DrugBank; DB00242; Cladribine.
DR   DrugBank; DB00631; Clofarabine.
DR   DrugBank; DB09065; Cobicistat.
DR   DrugBank; DB05239; Cobimetinib.
DR   DrugBank; DB00286; Conjugated Equine Estrogens.
DR   DrugBank; DB00091; Cyclosporine.
DR   DrugBank; DB08912; Dabrafenib.
DR   DrugBank; DB09102; Daclatasvir.
DR   DrugBank; DB00970; Dactinomycin.
DR   DrugBank; DB02115; Daidzin.
DR   DrugBank; DB09183; Dasabuvir.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00694; Daunorubicin.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB01248; Docetaxel.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB00470; Dronabinol.
DR   DrugBank; DB04881; Elacridar.
DR   DrugBank; DB11574; Elbasvir.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB00773; Etoposide.
DR   DrugBank; DB00973; Ezetimibe.
DR   DrugBank; DB03496; Flavopiridol.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB00158; Folic Acid.
DR   DrugBank; DB00317; Gefitinib.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB01016; Glyburide.
DR   DrugBank; DB01094; Hesperetin.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB09054; Idelalisib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00602; Ivermectin.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB00448; Lansoprazole.
DR   DrugBank; DB01097; Leflunomide.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB01204; Mitoxantrone.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB03467; Naringenin.
DR   DrugBank; DB00220; Nelfinavir.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB00698; Nitrofurantoin.
DR   DrugBank; DB01051; Novobiocin.
DR   DrugBank; DB00338; Omeprazole.
DR   DrugBank; DB09330; Osimertinib.
DR   DrugBank; DB00526; Oxaliplatin.
DR   DrugBank; DB01229; Paclitaxel.
DR   DrugBank; DB00213; Pantoprazole.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08860; Pitavastatin.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB00175; Pravastatin.
DR   DrugBank; DB00457; Prazosin.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB01129; Rabeprazole.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB08864; Rilpivirine.
DR   DrugBank; DB00740; Riluzole.
DR   DrugBank; DB08931; Riociguat.
DR   DrugBank; DB00503; Ritonavir.
DR   DrugBank; DB09291; Rolapitant.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB01232; Saquinavir.
DR   DrugBank; DB08934; Sofosbuvir.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB00795; Sulfasalazine.
DR   DrugBank; DB00669; Sumatriptan.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB04348; Taurocholic Acid.
DR   DrugBank; DB00966; Telmisartan.
DR   DrugBank; DB00444; Teniposide.
DR   DrugBank; DB08880; Teriflunomide.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB01030; Topotecan.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugBank; DB08881; Vemurafenib.
DR   DrugBank; DB11581; Venetoclax.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB00541; Vincristine.
DR   DrugBank; DB08828; Vismodegib.
DR   DrugBank; DB00549; Zafirlukast.
DR   DrugBank; DB00495; Zidovudine.
DR   GuidetoPHARMACOLOGY; 792; -.
DR   TCDB; 3.A.1.204.2; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; Q9UNQ0; -.
DR   PhosphoSitePlus; Q9UNQ0; -.
DR   BioMuta; ABCG2; -.
DR   DMDM; 67462103; -.
DR   PaxDb; Q9UNQ0; -.
DR   PeptideAtlas; Q9UNQ0; -.
DR   PRIDE; Q9UNQ0; -.
DR   DNASU; 9429; -.
DR   Ensembl; ENST00000237612; ENSP00000237612; ENSG00000118777. [Q9UNQ0-1]
DR   Ensembl; ENST00000515655; ENSP00000426917; ENSG00000118777. [Q9UNQ0-2]
DR   GeneID; 9429; -.
DR   KEGG; hsa:9429; -.
DR   UCSC; uc003hrg.4; human. [Q9UNQ0-1]
DR   CTD; 9429; -.
DR   DisGeNET; 9429; -.
DR   GeneCards; ABCG2; -.
DR   HGNC; HGNC:74; ABCG2.
DR   HPA; CAB037299; -.
DR   HPA; HPA054719; -.
DR   MIM; 138900; phenotype.
DR   MIM; 603756; gene.
DR   MIM; 614490; phenotype.
DR   neXtProt; NX_Q9UNQ0; -.
DR   OpenTargets; ENSG00000118777; -.
DR   PharmGKB; PA390; -.
DR   eggNOG; ENOG410IN8P; Eukaryota.
DR   eggNOG; COG0842; LUCA.
DR   GeneTree; ENSGT00740000114855; -.
DR   HOVERGEN; HBG050441; -.
DR   InParanoid; Q9UNQ0; -.
DR   KO; K05681; -.
DR   OMA; VDSSFYK; -.
DR   OrthoDB; EOG091G08QB; -.
DR   PhylomeDB; Q9UNQ0; -.
DR   TreeFam; TF105211; -.
DR   Reactome; R-HSA-2161517; Abacavir transmembrane transport.
DR   Reactome; R-HSA-917937; Iron uptake and transport.
DR   SABIO-RK; Q9UNQ0; -.
DR   ChiTaRS; ABCG2; human.
DR   GeneWiki; ABCG2; -.
DR   GenomeRNAi; 9429; -.
DR   PRO; PR:Q9UNQ0; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000118777; -.
DR   ExpressionAtlas; Q9UNQ0; baseline and differential.
DR   Genevisible; Q9UNQ0; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; TAS:ProtInc.
DR   GO; GO:0015232; F:heme transporter activity; TAS:Reactome.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0008559; F:xenobiotic-transporting ATPase activity; TAS:ProtInc.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; TAS:Reactome.
DR   GO; GO:0033344; P:cholesterol efflux; IBA:GO_Central.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   GO; GO:0046415; P:urate metabolic process; IMP:UniProtKB.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR013525; ABC_2_trans.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR030256; ABCG2.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR19241:SF422; PTHR19241:SF422; 1.
DR   Pfam; PF01061; ABC2_membrane; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Membrane; Mitochondrion;
KW   Nucleotide-binding; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    655       ATP-binding cassette sub-family G member
FT                                2.
FT                                /FTId=PRO_0000093386.
FT   TOPO_DOM      1    395       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    396    416       Helical. {ECO:0000255}.
FT   TOPO_DOM    417    428       Extracellular. {ECO:0000255}.
FT   TRANSMEM    429    449       Helical. {ECO:0000255}.
FT   TOPO_DOM    450    477       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    478    498       Helical. {ECO:0000255}.
FT   TOPO_DOM    499    506       Extracellular. {ECO:0000255}.
FT   TRANSMEM    507    527       Helical. {ECO:0000255}.
FT   TOPO_DOM    528    535       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    536    556       Helical. {ECO:0000255}.
FT   TOPO_DOM    557    630       Extracellular. {ECO:0000255}.
FT   TRANSMEM    631    651       Helical. {ECO:0000255}.
FT   TOPO_DOM    652    655       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       37    286       ABC transporter. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN      389    651       ABC transmembrane type-2.
FT   NP_BIND      80     87       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   SITE        418    418       Not glycosylated.
FT                                {ECO:0000269|PubMed:15807535}.
FT   SITE        557    557       Not glycosylated.
FT                                {ECO:0000269|PubMed:15807535}.
FT   CARBOHYD    596    596       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:15807535}.
FT   DISULFID    592    608       {ECO:0000269|PubMed:17686774}.
FT   DISULFID    603    603       Interchain.
FT                                {ECO:0000269|PubMed:17686774}.
FT   VAR_SEQ     550    611       IFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQN
FT                                FCPGLNATGNNPCNYATCTGE -> VCWSISQPLHLGCHGF
FT                                STSAFHDMDLRLCSIMNFWDKTSAQDSMQQETILVTMQHVL
FT                                AKNIW (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014232.
FT   VAR_SEQ     612    655       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014233.
FT   VARIANT      12     12       V -> M (found in Jr(a-) blood group
FT                                phenotype; dbSNP:rs2231137).
FT                                {ECO:0000269|PubMed:12111378,
FT                                ECO:0000269|PubMed:12544509,
FT                                ECO:0000269|PubMed:15838659,
FT                                ECO:0000269|PubMed:16702730,
FT                                ECO:0000269|PubMed:22246507,
FT                                ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020779.
FT   VARIANT      13     13       S -> L. {ECO:0000269|PubMed:16702730}.
FT                                /FTId=VAR_067363.
FT   VARIANT     141    141       Q -> K (polymorphism associated with high
FT                                serum levels of uric acid and increased
FT                                risk of gout; results in lower urate
FT                                transport rates compared to wild-type;
FT                                dbSNP:rs2231142).
FT                                {ECO:0000269|PubMed:12111378,
FT                                ECO:0000269|PubMed:12544509,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15838659,
FT                                ECO:0000269|PubMed:16702730,
FT                                ECO:0000269|PubMed:19506252,
FT                                ECO:0000269|Ref.11, ECO:0000269|Ref.8}.
FT                                /FTId=VAR_020780.
FT   VARIANT     160    160       R -> Q (in dbSNP:rs528655917).
FT                                {ECO:0000269|PubMed:16702730}.
FT                                /FTId=VAR_067364.
FT   VARIANT     166    166       Q -> E (in dbSNP:rs1061017).
FT                                {ECO:0000269|PubMed:12958161,
FT                                ECO:0000269|PubMed:9850061}.
FT                                /FTId=VAR_022704.
FT   VARIANT     206    206       I -> L (in dbSNP:rs12721643).
FT                                {ECO:0000269|PubMed:12544509}.
FT                                /FTId=VAR_022705.
FT   VARIANT     208    208       F -> S (in dbSNP:rs1061018).
FT                                {ECO:0000269|PubMed:12958161,
FT                                ECO:0000269|PubMed:9850061}.
FT                                /FTId=VAR_022706.
FT   VARIANT     248    248       S -> P (in dbSNP:rs3116448).
FT                                /FTId=VAR_022707.
FT   VARIANT     296    296       D -> H (in dbSNP:rs41282401).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_030357.
FT   VARIANT     316    316       T -> P. {ECO:0000269|Ref.9}.
FT                                /FTId=VAR_022443.
FT   VARIANT     354    354       G -> R (in dbSNP:rs138606116).
FT                                {ECO:0000269|PubMed:16702730}.
FT                                /FTId=VAR_067365.
FT   VARIANT     431    431       F -> L. {ECO:0000269|PubMed:15618737,
FT                                ECO:0000269|PubMed:16702730}.
FT                                /FTId=VAR_018349.
FT   VARIANT     441    441       S -> N. {ECO:0000269|PubMed:16702730}.
FT                                /FTId=VAR_067366.
FT   VARIANT     489    489       F -> L (in dbSNP:rs192169063).
FT                                {ECO:0000269|PubMed:15618737,
FT                                ECO:0000269|PubMed:16702730}.
FT                                /FTId=VAR_018350.
FT   VARIANT     528    528       A -> T (in dbSNP:rs45605536).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_030358.
FT   VARIANT     571    571       F -> I (in dbSNP:rs9282571).
FT                                /FTId=VAR_022708.
FT   VARIANT     590    590       N -> Y (in dbSNP:rs34264773).
FT                                {ECO:0000269|PubMed:12544509}.
FT                                /FTId=VAR_035355.
FT   VARIANT     620    620       D -> N (in dbSNP:rs34783571).
FT                                {ECO:0000269|PubMed:15838659}.
FT                                /FTId=VAR_022709.
FT   MUTAGEN      86     86       K->M: Inactive and altered subcellular
FT                                location. {ECO:0000269|PubMed:15769853}.
FT   MUTAGEN     418    418       N->Q: No effect.
FT                                {ECO:0000269|PubMed:15807535}.
FT   MUTAGEN     482    482       R->D: Decreases ATPase activity.
FT                                {ECO:0000269|PubMed:15670731}.
FT   MUTAGEN     482    482       R->G,N,S,T: Increases ATPase activity.
FT                                {ECO:0000269|PubMed:15670731}.
FT   MUTAGEN     482    482       R->K,I,M,Y: No change in ATPase activity.
FT                                {ECO:0000269|PubMed:15670731}.
FT   MUTAGEN     482    482       R->T,Y: Decreases transport activity.
FT                                {ECO:0000269|PubMed:15670731}.
FT   MUTAGEN     557    557       N->Q: No effect.
FT                                {ECO:0000269|PubMed:15807535}.
FT   MUTAGEN     583    583       H->A: Strongly reduced binding to hemin
FT                                but not to PPIX.
FT                                {ECO:0000269|PubMed:20705604}.
FT   MUTAGEN     596    596       N->Q: Loss of glycosylation.
FT                                {ECO:0000269|PubMed:15807535}.
FT   MUTAGEN     603    603       C->A: Strongly reduced binding to hemin
FT                                but not to PPIX.
FT                                {ECO:0000269|PubMed:20705604}.
FT   MUTAGEN     605    605       Y->A: No effect on hemin binding.
FT                                {ECO:0000269|PubMed:20705604}.
FT   CONFLICT     24     24       A -> V (in Ref. 1; AAD09188 and 7;
FT                                AAP44087). {ECO:0000305}.
FT   CONFLICT    315    316       Missing (in Ref. 10; BAA92050).
FT                                {ECO:0000305}.
FT   CONFLICT    390    390       G -> V (in Ref. 13; AAH92408).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       R -> G (in Ref. 14; AF093771/AF093772).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       R -> T (in Ref. 2; AAC97367).
FT                                {ECO:0000305}.
FT   CONFLICT    484    485       LP -> FT (in Ref. 14; AF093772).
FT                                {ECO:0000305}.
FT   CONFLICT    501    501       P -> A (in Ref. 6; AAG52982).
FT                                {ECO:0000305}.
SQ   SEQUENCE   655 AA;  72314 MW;  A8AF66B96034C5A8 CRC64;
     MSSSNVEVFI PVSQGNTNGF PATASNDLKA FTEGAVLSFH NICYRVKLKS GFLPCRKPVE
     KEILSNINGI MKPGLNAILG PTGGGKSSLL DVLAARKDPS GLSGDVLING APRPANFKCN
     SGYVVQDDVV MGTLTVRENL QFSAALRLAT TMTNHEKNER INRVIQELGL DKVADSKVGT
     QFIRGVSGGE RKRTSIGMEL ITDPSILFLD EPTTGLDSST ANAVLLLLKR MSKQGRTIIF
     SIHQPRYSIF KLFDSLTLLA SGRLMFHGPA QEALGYFESA GYHCEAYNNP ADFFLDIING
     DSTAVALNRE EDFKATEIIE PSKQDKPLIE KLAEIYVNSS FYKETKAELH QLSGGEKKKK
     ITVFKEISYT TSFCHQLRWV SKRSFKNLLG NPQASIAQII VTVVLGLVIG AIYFGLKNDS
     TGIQNRAGVL FFLTTNQCFS SVSAVELFVV EKKLFIHEYI SGYYRVSSYF LGKLLSDLLP
     MRMLPSIIFT CIVYFMLGLK PKADAFFVMM FTLMMVAYSA SSMALAIAAG QSVVSVATLL
     MTICFVFMMI FSGLLVNLTT IASWLSWLQY FSIPRYGFTA LQHNEFLGQN FCPGLNATGN
     NPCNYATCTG EEYLVKQGID LSPWGLWKNH VALACMIVIF LTIAYLKLLF LKKYS
//
